Cytokinetics, Incorporated
CYTK
$64.66
$1.151.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -751.94M | -606.31M | -615.26M | -589.53M | -576.40M |
| Total Depreciation and Amortization | 9.65M | 9.38M | 9.50M | 9.53M | 13.48M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 301.44M | 174.73M | 151.60M | 148.44M | 119.73M |
| Change in Net Operating Assets | 7.93M | -4.72M | 56.16M | 35.66M | 38.83M |
| Cash from Operations | -432.93M | -426.92M | -398.00M | -395.89M | -404.36M |
| Capital Expenditure | -20.45M | -11.80M | -9.57M | -3.91M | -2.69M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 219.17M | 236.45M | -470.21M | -549.19M | -742.68M |
| Cash from Investing | 198.72M | 224.65M | -479.78M | -553.10M | -745.37M |
| Total Debt Issued | 729.46M | -- | -- | -- | -- |
| Total Debt Repaid | -413.71M | -11.39M | -11.57M | -9.62M | -6.93M |
| Issuance of Common Stock | 27.81M | 27.20M | 644.34M | 759.86M | 922.40M |
| Repurchase of Common Stock | -2.43M | -1.71M | -1.20M | -19.63M | -18.45M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 75.00M | 75.00M | 200.00M | 200.00M | 200.00M |
| Cash from Financing | 416.14M | 89.10M | 831.57M | 930.61M | 1.10B |
| Foreign Exchange rate Adjustments | -614.00K | -786.00K | -88.00K | 209.00K | -103.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 181.32M | -113.97M | -46.30M | -18.17M | -52.80M |